Anti-CD70 CAR-T cells have shown an antitumor effect on RCC in preclinical studies leading to lysis of target cells and increased levels of IL-2, TNF-α, and IFN-γ released by CAR-T cells. This evidence concerns the gene TNF and renal cell carcinoma.